Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Significant Decrease in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 14,800 shares, adecreaseof35.9% from the July 15th total of 23,100 shares. Based on an average trading volume of 95,400 shares, the short-interest ratio is presently 0.2 days. Currently,0.4% of the company’s stock are sold short. Currently,0.4% of the company’s stock are sold short. Based on an average trading volume of 95,400 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd bought a new stake in Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Price Performance

Shares of VRAX stock opened at $0.7750 on Wednesday. The firm has a fifty day moving average of $0.86 and a 200-day moving average of $1.11. Virax Biolabs Group has a 12-month low of $0.7222 and a 12-month high of $7.63.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.